These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 8535306)
1. Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors. Broun ER; Nichols CR; Mandanas R; Salzman D; Turns M; Hromas R; Cornetta K; Einhorn LH Bone Marrow Transplant; 1995 Sep; 16(3):353-8. PubMed ID: 8535306 [TBL] [Abstract][Full Text] [Related]
2. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors. Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380 [TBL] [Abstract][Full Text] [Related]
3. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; Gonin R; McCauley M; Mazanet R; Schnipper L; Frei E Bone Marrow Transplant; 1995 Mar; 15(3):373-9. PubMed ID: 7599561 [TBL] [Abstract][Full Text] [Related]
4. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C; J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987 [TBL] [Abstract][Full Text] [Related]
5. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer. Margolin KA; Doroshow JH; Frankel P; Chow W; Leong LA; Lim D; McNamara M; Morgan RJ; Shibata S; Somlo G; Twardowski P; Yen Y; Kogut N; Schriber J; Alvarnas J; Stalter S Biol Blood Marrow Transplant; 2005 Nov; 11(11):903-11. PubMed ID: 16275593 [TBL] [Abstract][Full Text] [Related]
6. Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular cancer: the University of Michigan experience and literature review. Ayash LJ; Clarke M; Silver SM; Braun T; Uberti J; Ratanatharathorn V; Reynolds C; Ferrara J; Broun ER; Adams PT Bone Marrow Transplant; 2001 May; 27(9):939-47. PubMed ID: 11436104 [TBL] [Abstract][Full Text] [Related]
7. High-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation for the treatment of advanced malignancies: a phase I study. Saez RA; Slease RB; Strnad C; Selby GB; Confer DL; Epstein RB Bone Marrow Transplant; 1995 Oct; 16(4):507-14. PubMed ID: 8528165 [TBL] [Abstract][Full Text] [Related]
8. Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support. Elias AD; Wheeler C; Ayash LJ; Schwartz G; Ibrahim J; Mills L; McCauley M; Coleman N; Warren D; Schnipper L; Antman KH; Teicher BA; Frei E Clin Cancer Res; 1998 Jun; 4(6):1443-9. PubMed ID: 9626461 [TBL] [Abstract][Full Text] [Related]
9. A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer. Takahashi M; Yoshizawa H; Tanaka H; Tanaka J; Kagamu H; Ito K; Shimbo T; Chou D; Wakabayashi M; Suzuki E; Sakai K; Arakawa M; Gejyo F Bone Marrow Transplant; 2000 Jan; 25(1):5-11. PubMed ID: 10654007 [TBL] [Abstract][Full Text] [Related]
10. High dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors. Broun ER; Nichols CR; Tricot G; Loehrer PJ; Williams SD; Einhorn LH Bone Marrow Transplant; 1991 Jan; 7(1):53-6. PubMed ID: 1646050 [TBL] [Abstract][Full Text] [Related]
12. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome. Beyer J; Rick O; Weinknecht S; Kingreen D; Lenz K; Siegert W Bone Marrow Transplant; 1997 Nov; 20(10):813-9. PubMed ID: 9404920 [TBL] [Abstract][Full Text] [Related]
13. Long-term results of first-line sequential high-dose carboplatin, etoposide and ifosfamide chemotherapy with peripheral blood stem cell support for patients with advanced testicular germ cell tumor. Miki T; Mizutani Y; Akaza H; Ozono S; Tsukamoto T; Terachi T; Naito K; Nonomura N; Hara I; Yoshida O; Int J Urol; 2007 Jan; 14(1):54-9. PubMed ID: 17199861 [TBL] [Abstract][Full Text] [Related]
14. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study. Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474 [TBL] [Abstract][Full Text] [Related]
15. Tandem high-dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma. Lotz JP; Bouleuc C; André T; Touboul E; Macovei C; Hannoun L; Lefranc JP; Houry S; Uzan S; Izrael V Cancer; 1996 Jun; 77(12):2550-9. PubMed ID: 8640705 [TBL] [Abstract][Full Text] [Related]
16. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study. Snyder MJ; Johnson DB; Daly MB; Giguere JK; Harman GH; Harden EA; Johnson RA; Leff RS; Mercier RJ; Messerschmidt GL Bone Marrow Transplant; 1994 Oct; 14(4):595-600. PubMed ID: 7858534 [TBL] [Abstract][Full Text] [Related]
17. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. Lorch A; Kollmannsberger C; Hartmann JT; Metzner B; Schmidt-Wolf IG; Berdel WE; Weissinger F; Schleicher J; Egerer G; Haas A; Schirren R; Beyer J; Bokemeyer C; Rick O; J Clin Oncol; 2007 Jul; 25(19):2778-84. PubMed ID: 17602082 [TBL] [Abstract][Full Text] [Related]
18. Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer. Wandt H; Birkmann J; Denzel T; Schäfer K; Schwab G; Pilz D; Egger H; Both A; Gallmeier WM Bone Marrow Transplant; 1999 Apr; 23(8):763-70. PubMed ID: 10231137 [TBL] [Abstract][Full Text] [Related]
19. Feasibility and usefulness of high-dose chemotherapy (high-dose ifosfamide, carboplatin and etoposide) combined with peripheral blood stem cell transplantation for male germ cell tumor: a single-institute experience. Hara I; Miyake H; Yamada Y; Yamanaka K; Furukawa J; Kumano M; Takenaka A; Fujisawa M Anticancer Drugs; 2006 Oct; 17(9):1057-66. PubMed ID: 17001179 [TBL] [Abstract][Full Text] [Related]
20. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study. Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]